Literature DB >> 25212952

Secondary prevention of stroke in the elderly: focus on drug therapy.

Martinson K Arnan1, Gregory L Burke, Cheryl Bushnell.   

Abstract

Secondary stroke prevention in the elderly in many cases requires the use of drug therapy to maximize risk factor control. However, the elderly (≥65 years) are most likely to receive care that is not evidence-based, because of concerns for adverse events. In this review, we provide evidence to the practitioner in support of the value of blood pressure control with drug therapy to decrease recurrent stroke risk. This review also highlights evidence for the importance of statin therapy in stroke prevention among the elderly. Finally, the appropriate use of antiplatelet therapy and oral anticoagulation is addressed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25212952     DOI: 10.1007/s40266-014-0212-2

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  122 in total

1.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

2.  New guidelines to reduce risk of atherosclerotic cardiovascular disease: implications for stroke prevention in 2014.

Authors:  Philip B Gorelick; Larry B Goldstein; Bruce Ovbiagele
Journal:  Stroke       Date:  2014-02-20       Impact factor: 7.914

3.  Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.

Authors:  Amitava Banerjee; Deirdre A Lane; Christian Torp-Pedersen; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2011-12-21       Impact factor: 5.249

4.  Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall.

Authors:  Brian F Gage; Elena Birman-Deych; Roger Kerzner; Martha J Radford; David S Nilasena; Michael W Rich
Journal:  Am J Med       Date:  2005-06       Impact factor: 4.965

5.  Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).

Authors:  Josep Redon; Giuseppe Mancia; Peter Sleight; Helmut Schumacher; Peggy Gao; Janice Pogue; Robert Fagard; Paolo Verdecchia; Michael Weber; Michael Böhm; Bryan Williams; Khalid Yusoff; Koon Teo; Salim Yusuf
Journal:  J Am Coll Cardiol       Date:  2012-01-03       Impact factor: 24.094

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

7.  Total and high-density lipoprotein cholesterol and stroke risk.

Authors:  Yurong Zhang; Jaakko Tuomilehto; Pekka Jousilahti; Yujie Wang; Riitta Antikainen; Gang Hu
Journal:  Stroke       Date:  2012-04-10       Impact factor: 7.914

8.  Independent predictors of ischemic stroke in the elderly: prospective data from a stroke unit.

Authors:  Paola Forti; Fabiola Maioli; Gaetano Procaccianti; Valeria Nativio; Maria-Vittoria Lega; Maura Coveri; Marco Zoli; Tommaso Sacquegna
Journal:  Neurology       Date:  2012-12-12       Impact factor: 9.910

9.  Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study.

Authors:  Lars Peter Kammersgaard; H S Jørgensen; J Reith; H Nakayama; P M Pedersen; T S Olsen
Journal:  Age Ageing       Date:  2004-03       Impact factor: 10.668

10.  Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS): interpretation and implementation.

Authors:  John Chalmers; Stephen MacMahon
Journal:  J Hypertens Suppl       Date:  2003-06
View more
  6 in total

1.  Age-Related Differences in Non-Persistence with Statin Treatment in Patients after a Transient Ischaemic Attack.

Authors:  Martin Wawruch; Dusan Zatko; Gejza Wimmer; Jan Luha; Sona Wimmerova; Petra Matalova; Peter Kukumberg; Jan Murin; Tomas Tesar; Beata Havelkova; Rashmi Shah
Journal:  Clin Drug Investig       Date:  2017-11       Impact factor: 2.859

2.  Patient-Associated Characteristics Influencing the Risk for Non-Persistence with Statins in Older Patients with Peripheral Arterial Disease.

Authors:  Martin Wawruch; Gejza Wimmer; Jan Murin; Martina Paduchova; Tomas Tesar; Lubica Hlinkova; Peter Slavkovsky; Lubomira Fabryova; Emma Aarnio
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

3.  Efficacy and Safety of Loading-Dose Rosuvastatin Therapy in Elderly Patients with Acute Coronary Syndromes Undergoing Elective Percutaneous Coronary Intervention.

Authors:  Yungen Jiao; Feng Hu; Zhengang Zhang; Kaizheng Gong; Xiaoning Sun; Aihua Li; Naifeng Liu
Journal:  Clin Drug Investig       Date:  2015-12       Impact factor: 2.859

4.  Factors Influencing Non-Persistence with Antiplatelet Medications in Elderly Patients After Ischaemic Stroke.

Authors:  Martin Wawruch; Dusan Zatko; Gejza Wimmer; Jan Luha; Lenka Kuzelova; Peter Kukumberg; Jan Murin; Adam Hloska; Tomas Tesar; Zoltan Kallay; Rashmi Shah
Journal:  Drugs Aging       Date:  2016-05       Impact factor: 3.923

5.  Non-Persistence With Antiplatelet Medications Among Older Patients With Peripheral Arterial Disease.

Authors:  Martin Wawruch; Jan Murin; Tomas Tesar; Martina Paduchova; Miriam Petrova; Denisa Celovska; Beata Havelkova; Michal Trnka; Emma Aarnio
Journal:  Front Pharmacol       Date:  2021-05-19       Impact factor: 5.810

6.  Adherence to Antiplatelet Medications among Persistent and Non-Persistent Older Patients with Peripheral Arterial Disease.

Authors:  Martin Wawruch; Jan Murin; Tomas Tesar; Martina Paduchova; Miriam Petrova; Denisa Celovska; Petra Matalova; Beata Havelkova; Michal Trnka; Emma Aarnio
Journal:  Biomedicines       Date:  2021-11-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.